These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35358586)

  • 1. Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019.
    Leung J; Grosse SD; Hong K; Pesch MH; Lanzieri TM
    J Pediatr; 2022 Jul; 246():274-278.e2. PubMed ID: 35358586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015.
    Leung J; Dollard SC; Grosse SD; Chung W; Do T; Patel M; Lanzieri TM
    Clin Ther; 2018 Mar; 40(3):430-439.e1. PubMed ID: 29397198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States.
    Leung J; Grosse SD; Yockey B; Lanzieri TM
    J Pediatric Infect Dis Soc; 2022 Aug; 11(8):379-382. PubMed ID: 35532552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection.
    Garofoli F; Lombardi G; Angelini M; Campanini G; Zavattoni M; Baldanti F
    Int J Infect Dis; 2020 Sep; 98():150-152. PubMed ID: 32615325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful valganciclovir treatment initiated beyond 60 days of age in a preterm infant with congenital cytomegalovirus disease.
    Okahashi A; Hijikata M; Seimiya A; Nagano N; Yokota H; Kimura Y; Morioka I
    Pediatr Int; 2024; 66(1):e15755. PubMed ID: 38563289
    [No Abstract]   [Full Text] [Related]  

  • 6. Congenital Cytomegalovirus.
    Mestas E
    Adv Neonatal Care; 2016 Feb; 16(1):60-5. PubMed ID: 26752783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant).
    Morioka I; Kakei Y; Omori T; Nozu K; Fujioka K; Yoshikawa T; Moriuchi H; Ito Y; Oka A
    Medicine (Baltimore); 2020 Apr; 99(17):e19765. PubMed ID: 32332615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected hearing improvement after treatment with valganciclovir in a child with congenital cytomegalovirus infection.
    Palma S; Mazzoni L; Roversi MF; Botti C; Monzani D; Berardi A; Genovese E
    Folia Med (Plovdiv); 2021 Apr; 63(2):297-301. PubMed ID: 33932024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valganciclovir therapy for a neonate with congenital cytomegalovirus pneumonitis.
    Kanda R; Shimizu D; Hoshina T; Ogawa M; Kusuhara K
    Pediatr Int; 2021 Dec; 63(12):1526-1528. PubMed ID: 34399019
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection.
    Ohyama S; Morioka I; Fukushima S; Yamana K; Nishida K; Iwatani S; Fujioka K; Matsumoto H; Imanishi T; Nakamachi Y; Deguchi M; Tanimura K; Iijima K; Yamada H
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection.
    Yilmaz Çiftdogan D; Vardar F
    J Trop Pediatr; 2011 Apr; 57(2):132-4. PubMed ID: 20576693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the therapeutic approach to congenital cytomegalovirus infection.
    Garrido-Barbero M; Arnaez J; Garcia-Alix A
    Infection; 2020 Jun; 48(3):463-469. PubMed ID: 32125680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: An observational study.
    Bartlett AW; Hall BM; Palasanthiran P; McMullan B; Shand AW; Rawlinson WD
    J Clin Virol; 2018 Nov; 108():121-125. PubMed ID: 30300787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir for the treatment of cytomegalovirus infections in pediatric intestinal transplant recipients: A case series.
    Henry M; Leick M; Florescu DF; Keck M
    Pediatr Transplant; 2021 Sep; 25(6):e14034. PubMed ID: 34081375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus variation among newborns treated with valganciclovir.
    Dobbins GC; Kimberlin DW; Ross SA
    Antiviral Res; 2022 Jul; 203():105326. PubMed ID: 35504491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.
    Choi KY; Sharon B; Balfour HH; Belani K; Pozos TC; Schleiss MR
    J Clin Virol; 2013 Aug; 57(4):356-60. PubMed ID: 23688863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir Is Beneficial in Children with Congenital Cytomegalovirus and Isolated Hearing Loss.
    Pasternak Y; Ziv L; Attias J; Amir J; Bilavsky E
    J Pediatr; 2018 Aug; 199():166-170. PubMed ID: 29605391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment.
    Nishida K; Morioka I; Nakamachi Y; Kobayashi Y; Imanishi T; Kawano S; Iwatani S; Koda T; Deguchi M; Tanimura K; Yamashita D; Nibu K; Funakoshi T; Ohashi M; Inoue N; Iijima K; Yamada H
    Brain Dev; 2016 Feb; 38(2):209-16. PubMed ID: 26282917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of poor neurological development in patients with symptomatic congenital cytomegalovirus diseases after oral valganciclovir treatment.
    Fukushima S; Morioka I; Ohyama S; Nishida K; Iwatani S; Fujioka K; Mandai T; Matsumoto H; Nakamachi Y; Deguchi M; Tanimura K; Iijima K; Yamada H
    Brain Dev; 2019 Oct; 41(9):743-750. PubMed ID: 31072632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.